Program Book

Patients in the triamcinolone group received periocular injection of
triamcinolone acetonide (40 mg in 1 ml) at the time of plaque radiotherapy
and 4-months and 8-months later. Optical coherence tomography (OCT)
was performed at each patient evaluation.
Results. OCT-evident macular edema occurred significantly less often in
the triamcinolone group compared to the control group up to 36-months
following plaque radiotherapy (relative risk 0.61, 95% CI 0.46-0.81). At
36-month follow-up however, rates of moderate vision loss (loss of 3 or
more lines of best corrected visual acuity [BCVA]) and severe vision loss
(BCVA 10 mm in LBD) were included in this
prospective study. Patients were scheduled for I-125 brachytherapy
and randomized for adjuvant IVTA (4mg/0.1mL) or IVA (1.25mg/0.05mL)
injection performed at plaque removal. All patients underwent a 1, 3, 6
month follow-up examination, and every 6 months thereafter, including
fundus photography and A/B scan ultrasonography. Follow-up was
longer than 24 months.
Results. Follow-up was 37±7 months. Tumour regression was
achieved in all patients. Complete SRD regression was documented in
eighteen IVTA- treated patients (56%) vs eleven IVA-treated patients
(34%) (p